Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

41.40
+0.92002.27%
Post-market: 41.400.00000.00%19:30 EDT
Volume:1.46M
Turnover:60.32M
Market Cap:4.50B
PE:-22.38
High:41.94
Open:41.01
Low:40.42
Close:40.48
52wk High:48.51
52wk Low:14.25
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.70
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:10.03
PE(LYR):-25.40

Loading ...

Wedbush Raises Price Target on Edgewise Therapeutics to $52 From $46, Maintains Outperform Rating

MT Newswires Live
·
Jun 02

Edgewise Therapeutics price target raised to $66 from $52 at Raymond James

TIPRANKS
·
Jun 02

Sector Update: Healthcare Stocks Fall in Afternoon Trading

MT Newswires Live
·
Jun 02

Edgewise Therapeutics deal ‘looks really strong,’ says Stifel

TIPRANKS
·
Jun 02

Edgewise Therapeutics rises 17.5%

TIPRANKS
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Apple, JetBlue, Cognizant

Reuters
·
Jun 01

Edgewise Therapeutics confirms sale of sevasemten for up to $2.65B

TIPRANKS
·
Jun 01

Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology

TIPRANKS
·
Jun 01

Edgewise to Sell Muscular Dystrophy Unit in $2.65B Deal

Dow Jones
·
Jun 01

Edgewise Therapeutics Shares up 28% Premarket After Co to Sell Muscle Dystrophy Business to Servier for up to $2.65 Bln

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Employees in Muscular Dystrophy Business to Receive Comparable Offers From Servier

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Announces Sale of Sevasemten to Servier for up to $2.65 Bln

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: to Receive $1.55 Bln in Upfront Cash Consideration & Eligible for up to $1.1 Bln in Milestone Payments

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: Remains on Track to Initiate Phase 2 Trial of Edg-15400 in Heart Failure With Preserved Ejection Fraction

THOMSON REUTERS
·
Jun 01

Edgewise Therapeutics: on Track to Report 12-Week Cirrus-HCM Part D Data in Q2 2026

THOMSON REUTERS
·
Jun 01

Servier to buy Edgewise muscular dystrophy business for up to $2.65 billion

Reuters
·
Jun 01

Edgewise Therapeutics - Proceeds Expected to Fully Fund Edg-7500 Development Through Potential Approval

THOMSON REUTERS
·
Jun 01

Press Release: Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Dow Jones
·
Jun 01

Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)

TIPRANKS
·
May 26

Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi Year Shareholder Returns

Simply Wall St.
·
May 20